NEPHROSCAN

Peak

succimer

Evergreen Therapeutics
NDAINTRAVENOUSPOWDERPriority Review
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
30/100

Mechanism of Action

Lead Chelating Activity

Pharmacologic Class:

Lead Chelator

Company
ET
Evergreen Therapeutics
China - Hong Kong
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers